Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

Unified data also improves AI outputs. For example, by drawing up-to-date information from a variety of an organization’s ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

Crinetics’ acromegaly treatment will go up against several entrenched medicines. Elsewhere, Bristol Myers moved to sell Sotyktu online at a discount and regulators rejected a new version of Biogen’s ...